Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly

Leukemia Research

Volumn 32, Issue 8, 2008, Pages 1299-1303

  Alinari, Lapo ^a,b   Geskin, Larisa ^c   Grady, Terrence ^a   Baiocchi, Robert A ^a,b   Bechtel, Mark A ^a   Porcu, Pierluigi ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; S zary Syndrome; Subcutaneous administration; Very elderly

Indexed keywords

ALEMTUZUMAB; VALACICLOVIR; VALGANCICLOVIR;

AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG SAFETY; DRUG TOLERANCE; ELDERLY CARE; EPSTEIN BARR VIRUS; ERYTHEMA; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; NEUTROPENIA; PRIORITY JOURNAL; RECURRENCE RISK; SEZARY SYNDROME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS INFECTION; VIRUS REACTIVATION;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; SEZARY SYNDROME;

EID: 42749087486     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.009     Document Type: Article

References (17)

1. Kim Y.H., and Hoppe R.T. Mycosis fungoides and the Sézary Syndrome. Semin Oncol 26 (1999) 276-289
2. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
3. Lundin J., Hagberg H., Repp R., Cavallin-Stahl E., Freden S., Juliusson G., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101 (2003) 4267-4272
4. Lenihan D.J., Alencar A.J., Yang D., Kurzrock R., Keating M.J., and Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 104 (2004) 655-658
5. Kennedy G.A., Seymour J.F., Wolf M., Januszewicz H., Davison J., McCormack C., et al. Treatment of patients with advanced mycosis fungoides and Sezary Syndrome with alemtuzumab. Eur J Haematol 71 (2003) 250-256
6. Russell-Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 142 (2004) 16-21
7. Duvic M., et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (2001) 2456-2471
8. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007) 31-39
9. Dearden C.E., and Matutes E. Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract Res Clin Haematol 19 (2006) 795-810
10. Mone A.P., Cheney C., Banks A.L., Tridandapani S., Mehter N., Guster S., et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 20 (2006) 272-279
11. Querfeld C., Rosen S.T., Guitart J., Martone B., Rademaker A., and Kuzel T.M. Alemtuzumab (Campath-1H) in patients with erythrodermic cutaneous T-cell lymphoma (E-CTCL): the Northwestern University Experience. Blood 108 11 (2006) 2732a
12. Bernengo M.G., Quaglino P., Comessatti A., Ortoncelli M., Novelli M., Lisa F., et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica 92 (2007) 784-794
13. Vonderheid E.C., et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46 (2002) 95-106
14. Porcu P., Baiocchi R.A., Lee J., Lin T.S., Blum K., Grady T.P., et al. Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: preliminary results. Proceedings ASCO 24 (2006) 7594a
15. Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., et al. The international harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
16. Lundin J., Porwit-MacDonald A., Rossmann E.D., Karlsson C., Edman P., Rezvany M.R., et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18 (2004) 484-490
17. Hale G., Rebello P., Brettman L.R., Fegan C., Kennedy B., Kimby E., et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104 (2004) 948-955